MicroRNA, epigenetic machinery and lung cancer

Thoracic Cancer

Volumn 2, Issue 2, 2011, Pages 35-44

  Kumar, Rajeev ^a   Xi, Yaguang ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Epigenetic; Histone modification; Lung cancer; Methylation; MicroRNA

Indexed keywords

MICRORNA;

CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; DNA METHYLATION; EPIGENETICS; GENE CONTROL; HISTONE MODIFICATION; HUMAN; HUMAN GENOME; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; RNA CLEAVAGE; RNA SYNTHESIS; TRANSLATION REGULATION;

EID: 84861376712     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2011.00043.x     Document Type: Review

References (115)

1. Jemal A, Siegel R, Xu J etal. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86: 1867-76.
3. Haruki N, Saito H, Harano T etal. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett 2001; 162: 201-5.
4. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005; 32: 169-76.
5. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005; 23: 3219-26.
6. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-68.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
8. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-56.
9. Thiagalingam S, Cheng KH, Lee HJ etal. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983: 84-100.
10. Zhang Y, Chen L. DNA methylation and non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2010; 13: 821-6.
11. Yoshino M, Suzuki M, Tian L etal. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol 2009; 35: 1201-9.
12. Buckingham L, Penfield Faber L, Kim A etal. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010; 126: 1630-9.
13. He L. Posttranscriptional regulation of PTEN dosage by noncoding RNAs. Sci Signal 2010; 3: pe39.
14. Chen M, Voeller D, Marquez VE etal. Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. Int J Oncol 2010; 37: 963-71.
15. Bowman RV, Wright CM, Davidson MR etal. Epigenomic targets for the treatment of respiratory disease. Expert Opin Ther Targets 2009; 13: 625-40.
16. Du L, Pertsemlidis A. microRNA and lung cancer: tumors and 22-mers. Cancer Metastasis Rev 2010; 29: 109-22.
17. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer 2010; 103: 1144-8.
18. Nana-Sinkam SP, Geraci MW. MicroRNA in lung cancer. J Thorac Oncol 2006; 1: 929-31.
19. Ortholan C, Puissegur MP, Ilie M etal. MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 2009; 16: 1047-61.
20. Osada H, Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2010; 102: 9-17.
21. Tong AW. Small RNAs and non-small cell lung cancer. Curr Mol Med 2006; 6: 339-49.
22. Wang QZ, Xu W, Habib N etal. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets 2009; 9: 572-94.
23. Wu X, Piper-Hunter MG, Crawford M etal. MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 2009; 4: 1028-34.
24. Lodygin D, Tarasov V, Epanchintsev A etal. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-600.
25. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-9.
26. Tarasov V, Jung P, Verdoodt B etal. Differential regulation of microRNA by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586-93.
27. Raver-Shapira N, Marciano E, Meiri E etal. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-43.
28. Fabbri M, Garzon R, Cimmino A etal. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104: 15805-10.
29. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
30. Gregory RI, Yan KP, Amuthan G etal. The Microprocessor complex mediates the genesis of microRNA. Nature 2004; 432: 235-40.
31. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-31.
32. Lee Y, Kim M, Han J etal. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60.
33. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNA. Nat Struct Mol Biol 2006; 13: 1097-101.
34. Lee Y, Han J, Yeom KH etal. Drosha in primary microRNA processing. Cold Spring Harb Symp Quant Biol 2006; 71: 51-7.
35. Lund E, Guttinger S, Calado A etal. Nuclear export of microRNA precursors. Science 2004; 303: 95-8.
36. Yi R, Qin Y, Macara IG etal. Exportin-5 mediates the nuclear export of pre-microRNA and short hairpin RNAs. Genes Dev 2003; 17: 3011-6.
37. Croce CM, Calin GA. miRNA, cancer, and stem cell division. Cell 2005; 122: 6-7.
38. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
39. John B, Enright AJ, Aravin A etal. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
40. Hayashita Y, Osada H, Tatematsu Y etal. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-32.
41. Ebi H, Sato T, Sugito N etal. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009; 28: 3371-9.
42. Matsubara H, Takeuchi T, Nishikawa E etal. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007; 26: 6099-105.
43. Chou YT, Lin HH, Lien YC etal. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010; 70: 8822-31.
44. Hatley ME, Patrick DM, Garcia MR etal. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-93.
45. Zhang JG, Wang JJ, Zhao F etal. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411: 846-52.
46. Foss KM, Sima C, Ugolini D etal. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011; 6: 482-8.
47. Xi S, Yang M, Tao Y etal. Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One 2010; 5: e13764.
48. Liu X, Sempere LF, Ouyang H etal. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010; 120: 1298-309.
49. Yang Y, Li X, Yang Q etal. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet 2010; 200: 127-33.
50. Zhang JG, Guo JF, Liu DL etal. MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2. J Thorac Oncol 2011; [Epub ahead of print].
51. Chen Z, Zeng H, Guo Y etal. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010; 29. Online publication.
52. Zhang J, Du Y, Wu C etal. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 2010; 24: 1217-23.
53. Davidson MR, Larsen JE, Yang IA etal. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 2010; 5: e12560.
54. Sun Y, Fang R, Li C etal. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010; 396: 501-7.
55. Incoronato M, Garofalo M, Urso L etal. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010; 70: 3638-46.
56. Sun Y, Bai Y, Zhang F etal. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010; 391: 1483-9.
57. He XY, Chen JX, Zhang Z etal. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 2010; 136: 1023-8.
58. Trang P, Medina PP, Wiggins JF etal. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29: 1580-7.
59. Ceppi P, Mudduluru G, Kumarswamy R etal. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010; 8: 1207-16.
60. Duncavage E, Goodgame B, Sezhiyan A etal. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 2010; 5: 1755-63.
61. Yu L, Todd NW, Xing L etal. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 12: 2870-8.
62. Hu Z, Chen X, Zhao Y etal. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-6.
63. Bishop JA, Benjamin H, Cholakh H etal. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010; 16: 610-9.
64. Xing L, Todd NW, Yu L etal. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010; 23: 1157-64.
65. Patnaik SK, Kannisto E, Knudsen S etal. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45.
66. Barshack I, Lithwick-Yanai G, Afek A etal. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 2010; 206: 578-84.
67. Voortman J, Goto A, Mendiboure J etal. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70: 8288-98.
68. Xi Y, Nakajima G, Gavin E etal. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-74.
69. Wang B, Wang XF, Howell P etal. A personalized microRNA microarray normalization method using a logistic regression model. Bioinformatics 2010; 26: 228-34.
70. Fabbri M, Calin GA. Epigenetics and miRNA in human cancer. Adv Genet 2010; 70: 87-99.
71. Valeri N, Vannini I, Fanini F etal. Epigenetics, miRNA, and human cancer: a new chapter in human gene regulation. Mamm Genome 2009; 20: 573-80.
72. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253-62.
73. Tang M, Xu W, Wang Q etal. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Curr Genomics 2009; 10: 336-52.
74. Plass C, Shibata H, Kalcheva I etal. Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M. Nat Genet 1996; 14: 106-9.
75. Heller G, Zielinski CC, Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010; 29: 95-107.
76. Jeltsch A. Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem 2002; 3: 274-93.
77. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
78. Weber B, Stresemann C, Brueckner B etal. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6: 1001-5.
79. Okano M, Bell DW, Haber DA etal. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-57.
80. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-26.
81. Ulivi P, Zoli W, Calistri D etal. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006; 206: 611-5.
82. Iliopoulos D, Guler G, Han SY etal. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005; 24: 1625-33.
83. Brueckner B, Stresemann C, Kuner R etal. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007; 67: 1419-23.
84. Bueno MJ, Perez de Castro I, Gomez de Cedron M etal. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506.
85. Fazi F, Racanicchi S, Zardo G etal. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007; 12: 457-66.
86. Lujambio A, Ropero S, Ballestar E etal. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-9.
87. Gallardo E, Navarro A, Vinolas N etal. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30: 1903-9.
88. Sempere LF, Preis M, Yezefski T etal. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16: 4246-55.
89. Wang PY, Li YJ, Zhang S etal. Regulating A549 cells growth by ASO inhibiting miRNA expression. Mol Cell Biochem 2010; 339: 163-71.
90. Wiggins JF, Ruffino L, Kelnar K etal. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923-30.
91. Burk U, Schubert J, Wellner U etal. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9.
92. Gregory PA, Bert AG, Paterson EL etal. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
93. Korpal M, Lee ES, Hu G etal. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
94. Park SM, Gaur AB, Lengyel E etal. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
95. Kim H, Kwon YM, Kim JS etal. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006; 107: 1042-9.
96. Lin RK, Hsu HS, Chang JW etal. Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007; 55: 205-13.
97. Vallbohmer D, Brabender J, Yang D etal. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 2006; 8: 39-44.
98. Hervouet E, Vallette FM, Cartron PF. Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 2009; 4: 487-99.
99. Shen H, Wang L, Spitz MR etal. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 2002; 62: 4992-5.
100. Lin RK, Wu CY, Chang JW etal. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70: 5807-17.
101. Garzon R, Liu S, Fabbri M etal. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-8.
102. Nguyen T, Kuo C, Nicholl MB etal. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011; 6: 388-94.
103. Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer potential prognostic and therapeutic targets. In: Sioud M (ed.). Target Discovery and Validation Reviews and Protocolsed. Vol. 2. Humana Press Inc., Totowa, NJ 2007; 25-62.
104. Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006; 3: 285-90.
105. Funayama R, Ishikawa F. [Tumor-suppressing role of cellular senescence and chromatin structure]. Nippon Ronen Igakkai Zasshi 2007; 44: 546-50.
106. Gravina S, Vijg J. Epigenetic factors in aging and longevity. Pflugers Arch 2010; 459: 247-58.
107. Munoz-Najar UM, Neurath KM, Vumbaca F etal. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006; 25: 2379-92.
108. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007; 8: 383-93.
109. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 2009; 33: 1485-97.
110. Van Den Broeck A, Brambilla E, Moro-Sibilot D etal. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 2008; 14: 7237-45.
111. Scott GK, Mattie MD, Berger CE etal. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-81.
112. Roccaro AM, Sacco A, Jia X etal. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010; 116: 1506-14.
113. Zhang J, Yang Y, Yang T etal. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010; 103: 1215-20.
114. Tuddenham L, Wheeler G, Ntounia-Fousara S etal. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett 2006; 580: 4214-7.
115. Song B, Wang Y, Xi Y etal. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-74.